Physician profile
Howard E Schulman
NPI 1992898233
$690.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $85.38 · 2022: $12.54 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.73 | 2019-2020 | |
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| Tandem Diabetes Care, INC. | $102.54 | 2019 | |
| Smith+Nephew, INC. | $47.42 | 2019-2020 | |
| Astellas Pharma US INC | $40.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $25.54 | 2019 | |
| Abbott Laboratories | $21.09 | 2019 | |
| Acorda Therapeutics, INC | $19.00 | 2019 | |
| Novo Nordisk INC | $16.83 | 2019 | |
| Melinta Therapeutics, LLC | $16.31 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.49 | 2019 | |
| Amarin Pharma, INC. | $13.94 | 2020 | |
| Baxter Healthcare | $13.85 | 2019 | |
| Merck Sharp & Dohme LLC | $13.76 | 2020 | |
| Abbvie INC. | $13.42 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $12.54 | 2022 | |
| Genentech USA, INC. | $12.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.